Dangerous Drugs Citation, commencement and extent 1 1 This Order may be cited as the Misuse of Drugs (Designation) (Amendment) Order (Northern Ireland) 2018 and come into operation on 31st January 2018. 2 The Interpretation Act (Northern Ireland) 1954 shall apply to this Order as it applies to an Act of the Assembly. Amendment of the Misuse of Drugs (Designation) Order (Northern Ireland) 2001 2 1 The Misuse of Drugs (Designation) Order (Northern Ireland) 2001 is amended as follows. 2 In paragraph 1(a) of Part 1 of the Schedule— a Before “Bufotenine” insert— Adinazolam (1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3a][1,4]benzodiazepine-1-yl)-N,N-dimethylmethanamine) N-Benzyl-ethylphenidate Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) ; b after “Cathinone” insert— 4’-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one) Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) ; c after “Concentrate of poppy-straw” insert— Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine) 3,4-Dichloroethylphenidate 3,4-Dichloroethylphenidate (3,4-DCMP) Dichlazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1.3-dihydro-2H-1,4-benzodiazepin-2-one) Ethylnaphthidate Ethylphenidate ; d after “Eticyclidine” insert— Etizolam ; e after “Etryptamine” insert— Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one) Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) 4-Fluoroethylphenidate 4-Fluorometylphenidate Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one) ; f after “Gamma-butyrolactone” insert— 3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one) Isopropylphenidate (IPP or IPPD) ; g after “Lysergide and other N-alkyl derivatives of lysergamide” insert— Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one) ; h after “Methcathinone” insert— 4-Methylmethylphenidate Methylmorphenate Methylnaphthidate (HDMP-28) N -methyl-1-(thiophen-2-yl)propan-2-amine(methiopropamine or MPA) Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine) Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one) Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) Propylphenidate ; i after “Psilocin” insert— Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) ; j after “3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)” insert— 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-menthylbenzamide (U-47,700) . 3 For paragraph 1(pa)-(v) of Part 1 of the Schedule substitute— q Any compound structurally derived from 3-benzolindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, ( N -methylpiperidin-2-yl) methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent; r Any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxalkyl, cycloalkylmethyl, cycloalkylethyl, ( N -methylpiperidin-2-yl) methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantly ring to any extent; s Any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl ( N -methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent; sa any compound (not being clonitazene, etonitazene, acemetacin, atorvastatin, bazedoxifene, indomethacin, losartan, olmesartan, proglumetacin, telmisartan, viminol, zafirlukast or a compound for the time being specified in sub-paragraphs (h) to (s) above) structurally related to 1-penyl-3-(1-naphthoyl)indole (JWH-018), in that the four sub-structures, that is to say the indole ring, the pentyl substituent, the methanone linking group and the naphthyl ring, are linked together in a similar manner, whether or not any of the sub-structures have been modified, and whether or not substituted in any of the linked sub-structures with one or more univalent substituents and, where any of the sub-structures have been modified, the modifications of the sub-structures are limited to any of the following, that is to say— i replacement of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole, benzimidazole, pyrrolo[2,3-b]pyridine, pyrrolo[3,2-c]pyridine or pyrazolo[3,4-b]pyridine; ii replacement of the pentyl substituent with alkyl, alkenyl, benzyl, cycloalkylmenthyl, cycloalkylethyl, ( N -methylpiperidin-2-yl)methyl,2-(4-morpholinyl)ethyl or(tetrahydropyran-4-yl)methyl; iii replacement of the methanone linking group with an ethanone, carboxamide, carboxylate, methylene bridge or methane group; iv replacement of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantly, cycloalkyl, cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl, 1,2,3,4-tetrahydronaphythyl, quinolinyl, isoquinolinyl, 1-amino-1-oxopropan-2-yl, 1-hydroxy-1-oxopropan-2-yl, piperidinyl, morpholinyl, pyrrolidinyl, tetrahydropyranyl or piperazinyl; t Any compound (not being bupropion, diethylpropion, pyrovalerone or a compound for the time being specified in sub-paragraph (a) above) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways, that is to say— i by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl of halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents; ii by substitution at the 3-position with an alkyl substituent; iii by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure; u Any compound structurally derived from 2-aminopropan-1-one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say— i by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univarient substituents; ii by substitution at the 3-position with an alkyl substituent; iii by substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. v Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say— i by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups; ii by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxyl group; iii by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group. w 1-Phenylcyclohexylamine or any compound (not being eticyclidine, ketamine, phencyclidine, rolicyclidine, tenocyclidine tiletamine) structurally derived from 1-phenylcyclothexylamine or 2-amino-2-phenylcyclohexanone by modification in any of the following ways, that is to say— i by substitution at the nitrogen atom to any extent by alkyl, alkenyl or hydroxyalkyl groups, or replacement of the amino group with a 1-piperidyl, 1-pyrrolidyl or 1-azepyl group, whether or not the nitrogen containing ring is further substituted by one or more alkyl groups; ii by substitution in the phenyl ring to any extent by amino, alkyl, hydroxyl, alkoxy or halide substituents, whether or not further substituted in the phenyl ring to any extent; iii by substitution in the cyclohexyl or cyclohexanone ring by one or more alkyl substituents; iv by replacement of the phenyl ring with a thienyl ring. x Any compound (not being benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine) structurally derived from mescaline, 4-bromo-2,5-dimethoxy-α-methylphenethylamine, 2,5-dimethoxy-α,4-dimethylphenethylamine, N -hydroxytenamphetamine, or a compound specified in sub-paragraph (c) or (d) above, by substitution at the nitrogen atom of the amino group with a benzyl substituent, whether or not substituted in the phenyl ring of the benzyl group to any extent; y Any compound (not being a compound for the time being specified in sub-paragraph (c) above) structurally derived from 1-benzofuran,2,3-dihydro-1-benzofuran, 1H-indole, indoline, 1H-indene, or indane by substitution in the 6-membered ring with a 2-ethylamino substituent whether or not further substituted into the ring system to any extent with alkyl, alkoxy, halide or haloalkyl substituents and whether or not substituted in the ethylamino side-chain with one or more alkyl substituents. . Sealed with the Official Seal of the Department of Health on 10th January 2018 Mark Timoney A senior officer of the Department of Health